Site Search

Get Luxury News by Email

Live the Good Life

Categories more

Sections

Other

Alma + Universkin Introduce a New Era in Post-Procedure Skincare with FDA-Listed Daily Mineral Serum

Be the first to review this item!

#skincare #serum #selfcare #beauty
Published
02/26/2026 by

Alma, a global leader in energy-based medical and aesthetic technologies, together with dermatological science brand Universkin, today announced a key regulatory milestone with the successful acceptance by the U.S. Food and Drug Administration (FDA) of the Product Listing SPL for Universkin by Alma, Daily Mineral Serum SPF 50 Broad Spectrum.

Universkin by Alma, Daily Mineral Serum SPF 50 establishes a new category in dermatological care, a high-performance, mineral serum engineered specifically for immediate post-procedure use following laser, RF, IPL, microneedling, and chemical peels, strengthening physician loyalty and enhancing treatment outcomes.

At the core of the product is Universkin's proprietary DUAL-SHIELD 50 Technology, an advanced zinc-oxide dispersion architecture developed specifically for post-procedure skin. The system pairs a concentration of zinc oxide (24%) with an oil-continuous gel-emulsion structure that delivers broad-spectrum UV protection while actively managing residual heat in treated skin.

Unlike conventional mineral sunscreens that can trap heat and increase discomfort after laser or RF procedures, DUAL-SHIELD 50 incorporates micro-dispersed aqueous phases that function as thermal sinks, helping dissipate heat while maintaining photostability, transparency, and skin tolerance. This dual-layer approach enables the product to deliver an enhanced post-procedure comfort, positioning it as a dermatological recovery solution rather than a conventional cosmetic sunscreen.

As the global aesthetic procedures market continues to expand and regulatory scrutiny of chemical UV filters intensifies, demand for mineral-only, dermatologist-validated photoprotection is accelerating. Daily Mineral Serum SPF 50 positions Alma and Universkin at the convergence of medical aesthetics, dermatology, and premium skincare, a high-growth segment driven by physician recommendation and patient trust.

The FDA product listing acceptance represents the final regulatory step ahead of broad U.S. market visibility and supports near-term commercialization while reinforcing Alma's long-term strategy of building integrated treatment ecosystems that extend beyond devices into outcome-driven skin recovery solutions.

Comments